Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan · Delayed Price · Currency is JPY 3,985.00
+5.00 (0.13%)
Aug 25, 2026, 3:30 PM JST
Kaken Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 2,313 | 19,435 | 9,796 | 6,817 | 13,885 |
Depreciation & Amortization | 3,325 | 2,554 | 2,753 | 2,568 | 2,486 |
Loss (Gain) From Sale of Assets | -378 | 1,555 | 167 | 1,911 | 2,896 |
Loss (Gain) From Sale of Investments | -2,014 | 287 | -13 | -1 | -1 |
Other Operating Activities | -10,654 | -842 | -3,788 | -4,407 | -4,431 |
Change in Accounts Receivable | 1,843 | 3,577 | -4,559 | 972 | 392 |
Change in Inventory | -59 | -1,084 | -1,603 | -583 | 241 |
Change in Accounts Payable | -769 | 1,100 | 880 | 280 | -2,630 |
Change in Other Net Operating Assets | -4,686 | 3,198 | -1,056 | 1,696 | 498 |
Operating Cash Flow | -11,079 | 29,780 | 2,577 | 9,253 | 13,336 |
Operating Cash Flow Growth | - | 1055.61% | -72.15% | -30.62% | -7.26% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -2,996 | -4,138 | -1,861 | -1,987 | -2,986 |
Sale of Property, Plant & Equipment | 3,141 | - | 1 | 12 | 704 |
Cash Acquisitions | 16 | -15,378 | - | - | -4,975 |
Sale (Purchase) of Intangibles | -2,427 | -254 | -306 | -219 | -271 |
Investment in Securities | 2,915 | 120 | 516 | -195 | 5 |
Other Investing Activities | -334 | - | -4,204 | -238 | -365 |
Investing Cash Flow | 315 | -19,650 | -5,854 | -2,627 | -7,888 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Issuance of Common Stock | - | 7,764 | - | - | - |
Repurchase of Common Stock | -2,343 | -5,935 | - | -1,340 | -2,414 |
Common Dividends Paid | -6,498 | -7,198 | -5,657 | -5,649 | -5,714 |
Other Financing Activities | - | - | -1 | -1 | -1 |
Financing Cash Flow | -8,841 | -5,369 | -5,658 | -6,990 | -8,129 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Foreign Exchange Rate Adjustments | 225 | - | - | - | - |
Miscellaneous Cash Flow Adjustments | - | -1 | - | - | 1 |
Net Cash Flow | -19,380 | 4,760 | -8,935 | -364 | -2,680 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -14,075 | 25,642 | 716 | 7,266 | 10,350 |
Free Cash Flow Growth | - | 3481.28% | -90.15% | -29.80% | -16.58% |
Free Cash Flow Margin | -18.31% | 27.27% | 0.99% | 9.96% | 13.61% |
Free Cash Flow Per Share | -371.26 | 671.92 | 18.97 | 193.39 | 272.53 |
Levered Free Cash Flow | -14,293 | 22,980 | -1,299 | 7,486 | 8,025 |
Unlevered Free Cash Flow | -14,265 | 22,998 | -1,289 | 7,497 | 8,036 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 45 | 28 | 17 | 17 | 17 |
Cash Income Tax Paid | 10,654 | 836 | 3,788 | 4,409 | 4,431 |
Change in Working Capital | -3,671 | 6,791 | -6,338 | 2,365 | -1,499 |